BACKGROUND/AIMS: In CD34-positive acute myeloid leukaemia (AML), the leukaemia-initiating event likely takes place in the CD34+CD38- cell compartment. CD123 has been shown to be a unique marker of leukaemic stem cells within the CD34+CD38- compartment. The aim of this study was to identify the percentage of CD34+CD38-CD123+ cells in AML blasts, AML CD34+CD38- stem cells, and normal and regenerating bone marrow CD34+CD38- stem cells from non-myeloid malignancies. METHODS: Thirty-eight adult de novo AML patients with intention to treat were enrolled after the application of inclusion criteria from February 2012 to February 2017. The percentage of the CD34+CD38-CD123+ phenotype in the blast population at diagnosis was determined using a CD45-gating strategy and CD34+ backgating by flow cytometry. We studied the CD34+CD38-CD123+ fraction in AML blasts at diagnosis, and its utility as a unique phenotype for minimal residual disease (MRD) of AML patients. RESULTS: CD123+ cells were present in 97% of AML blasts in patients at diagnosis (median 90%; range 21-99%). CD123+ cells were also present in 97% of the CD34+CD38- compartment (median 0.8164%, range 0.0262-39.7%). Interestingly, CD123 was not present in normal and regenerating CD34+CD38- bone marrow stem cells (range 0.002- 0.067 and 0.004-0.086, respectively). CONCLUSION: The CD34+CD38-CD123+ phenotype is present in virtually all AML blasts and it may be used as a unique single phenotype for MRD detection in AML patients.
BACKGROUND/AIMS: In CD34-positive acute myeloid leukaemia (AML), the leukaemia-initiating event likely takes place in the CD34+CD38- cell compartment. CD123 has been shown to be a unique marker of leukaemic stem cells within the CD34+CD38- compartment. The aim of this study was to identify the percentage of CD34+CD38-CD123+ cells in AML blasts, AMLCD34+CD38- stem cells, and normal and regenerating bone marrow CD34+CD38- stem cells from non-myeloid malignancies. METHODS: Thirty-eight adult de novo AMLpatients with intention to treat were enrolled after the application of inclusion criteria from February 2012 to February 2017. The percentage of the CD34+CD38-CD123+ phenotype in the blast population at diagnosis was determined using a CD45-gating strategy and CD34+ backgating by flow cytometry. We studied the CD34+CD38-CD123+ fraction in AML blasts at diagnosis, and its utility as a unique phenotype for minimal residual disease (MRD) of AMLpatients. RESULTS:CD123+ cells were present in 97% of AML blasts in patients at diagnosis (median 90%; range 21-99%). CD123+ cells were also present in 97% of the CD34+CD38- compartment (median 0.8164%, range 0.0262-39.7%). Interestingly, CD123 was not present in normal and regenerating CD34+CD38- bone marrow stem cells (range 0.002- 0.067 and 0.004-0.086, respectively). CONCLUSION: The CD34+CD38-CD123+ phenotype is present in virtually all AML blasts and it may be used as a unique single phenotype for MRD detection in AMLpatients.
Authors: Lina Han; Jeffrey L Jorgensen; Chris Brooks; Ce Shi; Qi Zhang; Graciela M Nogueras González; Antonio Cavazos; Rongqing Pan; Hong Mu; Sa A Wang; Jin Zhou; Gheath Ai-Atrash; Stefan O Ciurea; Mike Rettig; John F DiPersio; Jorge Cortes; Xuelin Huang; Hagop M Kantarjian; Michael Andreeff; Farhad Ravandi; Marina Konopleva Journal: Clin Cancer Res Date: 2017-01-17 Impact factor: 12.531
Authors: L Muñoz; J F Nomdedéu; O López; M J Carnicer; M Bellido; A Aventín; S Brunet; J Sierra Journal: Haematologica Date: 2001-12 Impact factor: 9.941
Authors: Frederick R Appelbaum; Holly Gundacker; David R Head; Marilyn L Slovak; Cheryl L Willman; John E Godwin; Jeanne E Anderson; Stephen H Petersdorf Journal: Blood Date: 2006-02-02 Impact factor: 22.113
Authors: M L Guzman; S J Neering; D Upchurch; B Grimes; D S Howard; D A Rizzieri; S M Luger; C T Jordan Journal: Blood Date: 2001-10-15 Impact factor: 22.113
Authors: Johannes R Schmidt; Elke Rücker-Braun; Katharina Heidrich; Malte von Bonin; Friedrich Stölzel; Christian Thiede; Jan M Middeke; Gerhard Ehninger; Martin Bornhäuser; Johannes Schetelig; Kristin Schubert; Martin von Bergen; Falk Heidenreich Journal: Proteomes Date: 2018-02-12
Authors: Justin Watts; Tara L Lin; Alice Mims; Prapti Patel; Cynthia Lee; Anoush Shahidzadeh; Paul Shami; Elizabeth Cull; Christopher R Cogle; Eunice Wang; Fatih M Uckun Journal: Front Oncol Date: 2022-01-13 Impact factor: 6.244
Authors: Dilana Staudt; Heather C Murray; Tabitha McLachlan; Frank Alvaro; Anoop K Enjeti; Nicole M Verrills; Matthew D Dun Journal: Int J Mol Sci Date: 2018-10-16 Impact factor: 5.923